Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TriSalus Life SciencesTLSI 48 Price-to-Tangible-Book is 44.67 as of Sep. 15, 2026. GuruFocus rates TLSI with a GF Score™ of 48/100 and a GF Value™ of $3.78 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 703 Medical Devices & Instruments companies, TriSalus Life Sciences ranks worse than 98.15% on this metric.
The historical rank and industry rank for TriSalus Life Sciences's Price-to-Tangible-Book or its related term are showing as below:
TLSI'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 17.96 Med: 19.14 Max: 44.05
Current: 43.45
During the past 5 years, TriSalus Life Sciences's highest Price to Tangible Book Ratio was 44.05. The lowest was 17.96. And the median was 19.14.
TLSI's Price-to-Tangible-Book is ranked worse than 98.15% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 2.6
vs TLSI: 43.45
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
TriSalus Life Sciences Price-to-Tangible-Book Related Terms
TriSalus Life Sciences Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Price-to-Tangible-Book Chart
TLSI vs CV, RXST, TMCI: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
TriSalus Life Sciences (TLSI) has a Price-to-Tangible-Book of 44.67 as of Sep. 15, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on TriSalus Life Sciences and its competitors. According to the industry distribution chart, TriSalus Life Sciences ranks #690 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 98.2%.
Is TriSalus Life Sciences' Price-to-Tangible-Book too high?
TriSalus Life Sciences' current Price-to-Tangible-Book is 44.67. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.60. TriSalus Life Sciences' value of 44.67 is 1618.1% above this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #690 out of 703 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Price-to-Tangible-Book compare to CV and RXST?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #690 out of 703 companies for Price-to-Tangible-Book. This places TriSalus Life Sciences in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.60. TriSalus Life Sciences' value of 44.67 is 1618.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.60, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Price-to-Tangible-Book of 44.67 is 1618.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Price-to-Tangible-Book is 44.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $4.78 — trading 26.5% above its estimated fair value. The current Price-to-Tangible-Book is 44.67 and 1618.1% above the Medical Devices & Instruments industry median of 2.60. TriSalus Life Sciences' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Price-to-Tangible-Book is 44.67 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $4.78 is trading 26.5% above its estimated GF Value™ of $3.78.
GuruFocus considers TriSalus Life Sciences to be Modestly Overvalued.
Key valuation signals for TLSI:
Price-to-Tangible-Book: 44.67
GF Value™: $3.78 vs. price of $4.78 (26.5% above fair value)
Industry Position: 1618.1% above the Medical Devices & Instruments median (#690 of 703)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
48GF Score
Get the complete analysis for TLSI
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
